The results of the selection of 87 common and chronic diseases in the Guangdong Alliance are released!

Following the announcement of the proposed selection/alternative results of the Guangdong Alliance's centralized procurement of diclofenac and other drugs (the first batch) yesterday, this morning, the Guangdong Alliance also launched an official online quotation for the centralized procurement of common and chronic diseases
.
The centralized procurement of this alliance involves 87 common and chronic disease drugs.
A total of 252 pharmaceutical companies and 1,070 products can participate in the quotation.
In the end, 225 companies and 890 products completed the quotation within the specified quotation time
.
Antibacterial drugs are the highlight of this collection, and the industry's main focus has been on which of the many large varieties and highly competitive varieties will fall
.
The proposed selection results show that Baiyunshan Tianxin, Ruiyang Pharmaceutical, Chenxin Pharmaceutical and other companies led the selection
.
Since "the decline in corporate quotations ≥ 50%" is one of the important conditions for selection, some varieties have formulated selection strategies based on this decline
.
A price drop of ≥50% is an important condition for selection.
The Guangdong Alliance includes Guangdong, Shanxi, Henan, Jiangxi, Inner Mongolia, Xinjiang, Xinjiang Production and Construction Corps, etc.
(The specific participating provinces are subject to the notification of volume)
.
The main products involved in this collection are antibacterial drugs, hemostatic drugs, corticosteroid preparations for skin diseases, painkillers, cardiovascular disease drugs, psychostimulants, cough and cold drugs, digestive system and metabolic drugs,
etc.
In addition, it also includes three types of proprietary Chinese medicines: Baoeran, Huazhi, and Qingre Xiaoyanning
.
It is understood that after the announcement of the selection results of this centralized drug procurement, public medical institutions in the alliance area will select the selected products and fill in the pre-purchase volume for the first year as required
.
In this regard, Guangdong also released a reference value for the total amount of medication used by medical institutions in the previous year, which is about 10.
17 billion (tablets/grains/bags/supports/day)
.
Among the varieties involved, there are as many as 11 varieties of 1 billion
.
According to data from Minet.
com, in 2020, the sales of amoxicillin-clavulanate potassium injection exceeded 2.
7 billion yuan in public medical institutions in China; in the first half of 2021, the sales of the drug exceeded 1.
4 billion yuan, a year-on-year increase of 19.
06%
.
The sales of amoxicillin-clavulanate potassium oral normal-release dosage form reached 1.
788 billion yuan in 2019
.
In addition, the sales growth of ampicillin, erythromycin ethylsuccinate and other varieties increased significantly
.
In the first half of 2021, the sales growth of ampicillin and erythromycin ethylsuccinate in public medical institutions in China was 176.
35% and 115.
28% respectively
.
On the whole, the varieties involved in this centralized procurement mainly focus on domestic enterprises, and there are not many varieties of foreign enterprises
.
Focusing on enterprises, 11 enterprises including Baiyunshan Tianxin, Ruiyang Pharmaceutical, Guangdong Nanguo, Sinopharm Rongsheng, and Chenxin Pharmaceutical all involved more than 10 varieties
.
From the perspective of variety competition, there are more than 30 companies competing for 5 varieties of ribavirin injection, vitamin C injection, lincomycin injection, vitamin B6 and gentamicin
.
As many as 49 companies meet the purchase order of Ribavirin Injection B, involving companies such as CSPC Ouyi and Shandong Xinhua, and the competition is the most intense
.
A price war for these varieties is clearly inevitable
.
The results show that the average price of ribavirin injection is about 0.
42 yuan or less, which is about 50% lower than the highest effective declared price
.
Unregistered products or included in monitoring In terms of price, according to the requirements, the quotation of the enterprise should not be higher than the purchase price (weighted average) of the Guangdong medical institution of the enterprise in the previous year
.
If it is higher than that, the winning result needs to be leveled; if the leveling is not accepted, it will be regarded as giving up the winning status
.
And since there is only one quotation opportunity for each price declaration product, companies are extra cautious in their quotations
.
According to the rules, the selection results of over-evaluation/non-over-evaluation/A purchase order/B purchase order are formed by bidding for each category or each purchase order.
Determine the company to be selected
.
On the whole, "lower comparable unit price" and "enterprise quotation drop ≥50.
00%" are important conditions for winning the bid
.
It is worth noting that for the products that belong to the scope of this centralized procurement but have not been registered, and the products that have not been selected in the same group, the medical institutions in Guangdong Province will conduct independent procurement as required.

.
Union provinces (regions) are subject to the regulations of the provinces (regions) for filing or monitoring products
.
Following 132 proprietary Chinese medicines and 276 chemical medicines, plus 87 medicines for common and chronic diseases, the Guangdong Alliance has reached 495 varieties in three batches, ranking first in both quantity and scale, basically achieving the "14th Five-Year Plan" ahead of schedule As mentioned in the National Medical Insurance Plan, "at the end of the 14th Five-Year Plan period, each province will be at the forefront of the country through the national and provincial centralized procurement of more than 500 drug varieties"
.
Antibacterial drugs are the key varieties of centralized procurement.
Looking at the whole country, as the category with the leading amount of clinical drug use in China, antibacterial drugs have always been the key varieties of centralized procurement
.
However, in recent years, the growth rate of the antibacterial drug market has slowed down under the policy of restricting shipments and limiting resistance
.
According to data from Minet.
com, under the further impact of centralized procurement and the epidemic, in 2020 China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminal systemic antibacterial drugs dropped sharply by 26.
45% %, sales exceeded 110 billion yuan; in the first half of 2021, its sales exceeded 58 billion yuan, a slight increase of 4.
03%
.
Sales of terminal systemic antibacterial drugs in Chinese public medical institutions (unit: 10,000 yuan) Up to now, in addition to the antibacterial drugs that have been included in the national procurement, more than 20 varieties of systemic antibacterial drugs have met the national centralized procurement conditions
.
Varieties with sufficient competition will be the first choice for centralized procurement.
Among them, there are 16 generic drugs that have been evaluated by 3 or more companies
.
The sales of 7 drugs exceeded 2 billion yuan, and the sales of meropenem injections reached 6 billion yuan, which have been included in the seventh batch of national procurement
.
At the executive meeting of the State Council at the beginning of this year, it was clarified that this year's centralized drug procurement will focus on chronic diseases and common diseases.
It is planned that by the end of this year, the national and provincial centralized drug procurement will reach more than 350 drugs in each province
.
It is a general trend for countries and localities to incorporate more common and chronic diseases into centralized procurement, and the market segment will usher in a new round of rapid reshuffle
.
appendix .